The Impact of Pharmacist-Based Services Across the Spectrum of Outpatient Heart Failure Therapy
Purpose of review
A multidisciplinary approach is vital to reduce mortality and hospitalizations in patients with heart failure. As members of the multidisciplinary team, pharmacists are uniquely positioned to care for patients across the spectrum of heart failure. This comprehensive review explores the different facets in which pharmacists can be utilized to impact the care for patients with heart failure, including those with cardiac transplant and left ventricular assist devices (LVADs), in the outpatient setting.
Pharmacists can see heart failure patients in a variety of settings to reduce drug therapy–related issues, increase use of guideline-directed medical therapy (GDMT), and reduce hospitalizations. Although there is limited data available, pharmacists have also been described in aiding the therapeutic drug monitoring of warfarin for patients with LVADs and immunosuppression agents in the transplant population.
Through collaborative practice agreements, pharmacists can provide progressive services such as titration of GDMT and lab monitoring, in addition to medication reconciliation, education, and review for potential drug-related problems. Pharmacists can increase access to patient care by providing services through distance-visits, shared medical appointments, and home visits.
KeywordsHeart failure Pharmacist-based services Outpatient therapy
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Mozaffarian. Heart Disease and stroke statistics-2016 update: a report from the American Heart Association (vol 133, pg e38, 2016). Circulation. 2016;133(15):E599.Google Scholar
- 2.Page RL. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association (vol 134, pg e32, 2016). Circulation. 2016;134(12):E261.Google Scholar
- 4.•• Milfred-Laforest SK, et al. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. J Card Fail. 2013;19(5):354–69. First opinion paper describing the benefits of clinical pharmacy services in patients with heart failure.PubMedGoogle Scholar
- 5.•• Dunn SP, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 2015;66(19):2129–39. Describes the training and qualifications of clinical pharmacist to provide care for patients with cardiovascular diseases. Provides a systematic review of summarizing pharmacy services provided to patients with cardiovascular disease.PubMedGoogle Scholar
- 10.Yates L, Valente, M, Wadsworth C. Evaluation of pharmacist medication review service in an outpatient Heart Failure Clinic. J Pharm Pract. 2019;897190019842696.Google Scholar
- 15.Singh-Franco D, Li L, Hannah S, Diamond M. Role of clinical pharmacist in a heart failure clinic. Hosp Pharm. 2005;40(10):890–6.Google Scholar
- 20.Bleske BE, Dillman NO, Cornelius D, Ward JK, Burson SC, Diez HL, et al. Heart failure assessment at the community pharmacy level: a feasibility pilot study. J Am Pharm Assoc (2003). 2014;54(6):634–41.Google Scholar
- 22.Laufs U, Griese-Mammen N, Krueger K, Wachter A, Anker SD, Koehler F, et al. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study. Eur J Heart Fail. 2018;20(9):1350–9.PubMedGoogle Scholar
- 23.• Schulz M, Griese-Mammen N, Anker SD, Koehler F, Ihle P, Ruckes C, et al. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. Eur J Heart Fail. 2019Recent large randomized control trial demonstrating the positive impact of pharmacist in the community setting on medication adherence.Google Scholar
- 24.Yancy CW, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.PubMedGoogle Scholar
- 25.Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organized program to initiate lifesaving treatment in hospitalized patients with heart failure). Am J Cardiol. 2008;102(11):1524–9.PubMedGoogle Scholar
- 29.Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159(16):1939–45.PubMedGoogle Scholar
- 30.Al-Bawardy R, et al. Heart failure postdischarge clinic: a pharmacist-led approach to reduce readmissions. Curr Probl Cardiol. 2019.Google Scholar
- 32.Donaho EK, Hall AC, Gass JA, Elayda MA, Lee VV, Paire S, et al. Protocol-driven allied health post-discharge transition clinic to reduce hospital readmissions in heart failure. J Am Heart Assoc. 2015;4(12).Google Scholar
- 47.Murphy JA, Schroeder MN, Rarus RE, Yakubu I, McKee SOP, Martin SJ. Implementation of a cardiac transitions of care pilot program: a prospective study of inpatient and outpatient clinical pharmacy services for patients with heart failure exacerbation or acute myocardial infarction. J Pharm Pract. 2019;32(1):68–76.PubMedGoogle Scholar
- 53.Kirsh S, Watts S, Pascuzzi K, O'Day ME, Davidson D, Strauss G, et al. Shared medical appointments based on the chronic care model: a quality improvement project to address the challenges of patients with diabetes with high cardiovascular risk. Qual Saf Health Care. 2007;16(5):349–53.PubMedPubMedCentralGoogle Scholar
- 54.Edelman D, et al. In Shared medical appointments for chronic medical conditions: a systematic review. Washington (DC); 2012.Google Scholar
- 60.Kalista T, Lemay V, Cohen L. Postdischarge community pharmacist-provided home services for patients after hospitalization for heart failure. J Am Pharm Assoc (2003). 2015;55(4):438–42.Google Scholar
- 65.Department for Health and Human Services, Centers for Medicare & Medicaid Services. Medicare program; hospital conditions of participation: requirements for approval and reapproval of transplant centers to prefrom organ transplants. Fed Regist. 2007;72(61):15198–280.Google Scholar
- 66.United Network for Organ Sharing. 2015. Appendix D of UNOS bylaws: changes in key transplant program personnel. https://unos.org/wp-content/uploads/unos/UNOS_Bylaws.pdf. Accessed 29 May 2019.
- 68.Gellatly RMLC. The addition of a specialist pharmacist to heart transplant and ventricular assist device clinics-early TRANDS in patient care [abstract]. J Heart Lung Transplant. 2015;34:S240–1.Google Scholar
- 71.Bissonnette J, Woodend K, Davies B, Stacey D, Knoll GA. Evaluation of a collaborative chronic care approach to improve outcomes in kidney transplant recipients. Clin Transpl. 2013;27(2):232–8.Google Scholar
- 74.Bishop MA, Streiff MB, Ensor CR, Tedford RJ, Russell SD, Ross PA. Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. ASAIO J. 2014;60(2):193–8.PubMedGoogle Scholar
- 77.American Pharmacists Association, F. and A. American Pharmacists. Consortium recommendations for advancing pharmacists’ patient care services and collaborative practice agreements. J Am Pharm Assoc (2003). 2013;53(2):e132–41.Google Scholar
- 78.•• Centers for Disease Control and Prevention. Advancing team-based care through collaborative practice agreement: a resource and implementation guide for adding pharmacists to the care team. Atlanta: Centers for Disease Control and Prevention, U.S. Department fo Health and Human Services; 2017. This guide provides an outline of the steps needed to incorporate pharmacists into the ambulatory care setting through the use of collaborative practice agreements.Google Scholar
- 79.Hazlet TK, Karwaki TE, Downing DF. Pathway to pharmacist medical provider status in Washington State. J Am Pharm Assoc (2003). 2017;57(1):116–9.Google Scholar
- 82.Department for Health and Human Services, Centers for Medicare & Medicaid Services. Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Procurement Organization Reporting and Communication; Transplant Outcome Measures and Documentation Requirements; Electronic Health Record (EHR) Incentive Programs; Payment to Nonexcepted Off-Campus ProviderBased Department of a Hospital; Hospital Value-Based Purchasing (VBP) Program; Establishment of payment rates under the medicare physician fee schedule for nonexcepted items and services furnished by an off-campus provider-based Department of a Hospital Federal Register. 2016;81(219):79562–79892.Google Scholar